Top

Drugs & Aging

Published in:

01-02-2022 | Opioids | Original Research Article

Medical Cannabis Use Among Older Adults in Canada: Self-Reported Data on Types and Amount Used, and Perceived Effects

Authors: Shankar Tumati, Krista L. Lanctôt, RuoDing Wang, Abby Li, Andrew Davis, Nathan Herrmann

Published in: Drugs & Aging | Issue 2/2022

Abstract

Background

Medical cannabis use is growing among older adults. In this retrospective study, we aimed to assess the characteristics of older medical cannabis users including the indications, type and amount of cannabis used, perceived changes in symptoms after cannabis use, change in dose of concurrent medications, and adverse effects.

Methods

Data were collected between October 2014 and October 2020 from patients who were consulting the Canada-wide network of clinics of a medical cannabis provider and who were willing to answer questionnaires based on their medical status. The current study included older adults (≥ 65 years) who completed questionnaires at intake and first follow-up visits. Data were summarized with descriptive statistics, which were compared between men and women with t tests or chi-squared tests. Tests of proportions assessed categorical responses for perceived effects after cannabis use. Logistic regression was used to assess trends in cannabis usage.

Results

Data included that from 9766 older adult users at intake (mean ± SD age = 73.2 ± 6.8 years, females = 60.0%), among whom 4673 (females = 61.4%) returned for follow-up after 90.6 ± 58 days. The most common primary indication for which medical cannabis was sought was pain (67.7%), which was more common in women, whereas oncological and neurological conditions were more common in men. At follow-up, cannabis oil was used by 81.0% of older adults, among whom compositions containing only or mostly cannabidiol (CBD) had been used by 83.6%. Adverse effects reported by older adults at the follow-up visit included dry mouth (12.8%), drowsiness (8.6%), and dizziness (4.0%). The majority of older adults reported improvements in pain (72.7%, z = 1482.6, p < 0.0001, compared to worsening or no change), sleep (64.5%, z = 549.4, p < 0.0001), and mood (52.8%, z = 16.4, p < 0.0001), with 35.6% reporting use of a reduced dose of opioids and 19.9% a reduced dose of benzodiazepines.

Interpretation

Among older adults, medical cannabis is used more often by women, with CBD-containing cannabis oils being the most commonly used. Users reported improved pain, sleep, and mood symptoms at follow-up after cannabis use. This study describes the patterns of use of medical cannabis by older adults and highlights the need for research to determine appropriate indications, precise doses of active ingredients, and short- and long-term outcomes among older adults.

Available only for authorised users

Bridgeman MB, Abazia DT. Medicinal Cannabis: history, pharmacology, and implications for the acute care setting. Pharm Ther. 2017;42:180–8.

Levine HG. Global drug prohibition: its uses and crises. Int J Drug Policy. 2003;14:145–53. https://doi.org/10.1016/S0955-3959(03)00003-3.CrossRef

Fazey CSJ. The commission on narcotic drugs and the United Nations International Drug Control Programme: politics, policies and prospect for change. Int J Drug Policy. 2003;14:155–69. https://doi.org/10.1016/S0955-3959(03)00004-5.CrossRef

Fischer B, Kuganesan S, Room R. Medical Marijuana programs: implications for cannabis control policy—observations from Canada. Int J Drug Policy. 2015;26:15–9. https://doi.org/10.1016/j.drugpo.2014.09.007.PubMedCrossRef

Health Canada. Understanding the New Access to Cannabis for Medical Purposes Regulations [Internet]. aem. 2016. https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/understanding-new-access-to-cannabis-for-medical-purposes-regulations.html. Accessed 11 May 2021

Health Canada. Data on cannabis for medical purposes [Internet]. 2020. https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/research-data/medical-purpose.html. Accessed 28 Jul 2021

Rotermann M, Langlois K. Prevalence and correlates of marijuana use in Canada, 2012. Health Rep. 2015;26:10–5.PubMed

Government of Canada. Cannabis Legalization and Regulation [Internet]. 2018. https://www.justice.gc.ca/eng/cj-jp/cannabis/. Accessed 11 May 2021

Hajizadeh M. Legalizing and regulating marijuana in Canada: review of potential economic, social, and health impacts. Int J Health Policy Manag. 2016;5:453–6. https://doi.org/10.15171/ijhpm.2016.63.PubMedPubMedCentralCrossRef

10.

Rotermann M. Looking back from 2020, how cannabis use and related behaviours changed in Canada. Health Rep. 2021;32:3–14. https://doi.org/10.25318/82-003-x202100400001-eng.PubMedCrossRef

11.

Han BH, Sherman S, Mauro PM, Martins SS, Rotenberg J, Palamar JJ. Demographic trends among older cannabis users in the United States, 2006–13. Addiction. 2017;112:516–25. https://doi.org/10.1111/add.13670.PubMedCrossRef

12.

Salas-Wright CP, Vaughn MG, Cummings-Vaughn LA, Holzer KJ, Nelson EJ, AbiNader M, et al. Trends and correlates of marijuana use among late middle-aged and older adults in the United States, 2002–2014. Drug Alcohol Depend. 2017;171:97–106. https://doi.org/10.1016/j.drugalcdep.2016.11.031.PubMedCrossRef

13.

Statistics Canada. National Cannabis Survey, third quarter 2019 [Internet]. 2019. https://www150.statcan.gc.ca/n1/daily-quotidien/191030/dq191030a-eng.htm. Accessed 20 May 2021

14.

Hazekamp A, Ware MA, Muller-Vahl KR, Abrams D, Grotenhermen F. The medicinal use of cannabis and cannabinoids—an international cross-sectional survey on administration forms. J Psychoact Drugs. 2013;45:199–210. https://doi.org/10.1080/02791072.2013.805976.CrossRef

15.

Kaskie B, Ayyagari P, Milavetz G, Shane D, Arora K. The increasing use of cannabis among older Americans: a public health crisis or viable policy alternative? Gerontologist. 2017;57:1166–72. https://doi.org/10.1093/geront/gnw166.PubMedCrossRef

16.

Hasin DS, Saha TD, Kerridge BT, Goldstein RB, Chou SP, Zhang H, et al. Prevalence of marijuana use disorders in the United States between 2001–2002 and 2012–2013. JAMA Psychiat. 2015;72:1235–42. https://doi.org/10.1001/jamapsychiatry.2015.1858.CrossRef

17.

Health Canada. Canadian Cannabis Survey 2020: Summary [Internet]. 2020. https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/research-data/canadian-cannabis-survey-2020-summary.html. Accessed 20 May 2021

18.

Treister-Goltzman Y, Freud T, Press Y, Peleg R. Trends in publications on medical cannabis from the year 2000. Popul Health Manag. 2019;22:362–8. https://doi.org/10.1089/pop.2018.0113.PubMedCrossRef

19.

Baumbusch J, Yip IS. Exploring new use of cannabis among older adults. Clin Gerontol. 2021;44:25–31. https://doi.org/10.1080/07317115.2020.1746720.PubMedCrossRef

20.

Bobitt J, Qualls SH, Schuchman M, Wickersham R, Lum HD, Arora K, et al. Qualitative analysis of cannabis use among older adults in Colorado. Drugs Aging. 2019;36:655–66. https://doi.org/10.1007/s40266-019-00665-w.PubMedCrossRef

21.

Manning L, Bouchard L. Medical cannabis use: exploring the perceptions and experiences of older adults with chronic conditions. Clin Gerontol. 2021;44:32–41. https://doi.org/10.1080/07317115.2020.1853299.PubMedCrossRef

22.

Ng JY, Gilotra K, Usman S, Chang Y, Busse JW. Attitudes toward medical cannabis among family physicians practising in Ontario, Canada: a qualitative research study. CMAJ Open. 2021;9:E342–8. https://doi.org/10.9778/cmajo.20200187.PubMedPubMedCentralCrossRef

23.

Allan GM, Ramji J, Perry D, Ton J, Beahm NP, Crisp N, et al. Simplified guideline for prescribing medical cannabinoids in primary care. Can Fam Physician. 2018;64:111–20.PubMedPubMedCentral

24.

Haug NA, Padula CB, Sottile JE, Vandrey R, Heinz AJ, Bonn-Miller MO. Cannabis use patterns and motives: a comparison of younger, middle-aged, and older medical cannabis dispensary patients. Addict Behav. 2017;72:14–20. https://doi.org/10.1016/j.addbeh.2017.03.006.PubMedPubMedCentralCrossRef

25.

Choi NG, DiNitto DM. Comparing older nonmedical and medical cannabis users: health-related characteristics, cannabis use patterns, and cannabis sources. Am J Drug Alcohol Abuse. 2021;47:612–22. https://doi.org/10.1080/00952990.2021.1908318.PubMedCrossRef

26.

Abuhasira R, Schleider LB-L, Mechoulam R, Novack V. Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly. Eur J Intern Med. 2018;49:44–50. https://doi.org/10.1016/j.ejim.2018.01.019.PubMedCrossRef

27.

Brown JD, Costales B, van Boemmel-Wegmann S, Goodin AJ, Segal R, Winterstein AG. Characteristics of older adults who were early adopters of medical cannabis in the Florida medical marijuana use registry. J Clin Med. 2020;9:1166. https://doi.org/10.3390/jcm9041166.PubMedCentralCrossRef

28.

Velayudhan L, McGoohan K, Bhattacharyya S. Safety and tolerability of natural and synthetic cannabinoids in adults aged over 50 years: a systematic review and meta-analysis. PLoS Med. 2021;18: e1003524. https://doi.org/10.1371/journal.pmed.1003524.PubMedPubMedCentralCrossRef

29.

Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313:2456–73. https://doi.org/10.1001/jama.2015.6358.PubMedCrossRef

30.

Briscoe J, Casarett D. Medical marijuana use in older adults. J Am Geriatr Soc. 2018;66:859–63. https://doi.org/10.1111/jgs.15346.PubMedCrossRef

31.

Beauchet O. Medical cannabis use in older patients: update on medical knowledge. Maturitas. 2018;118:56–9. https://doi.org/10.1016/j.maturitas.2018.10.010.PubMedCrossRef

32.

Fitzcharles M-A, Shir Y, Häuser W. Medical cannabis: strengthening evidence in the face of hype and public pressure. CMAJ. 2019;191:E907–8. https://doi.org/10.1503/cmaj.190509.PubMedPubMedCentralCrossRef

33.

National Survey of Drug Use and Health. 2019 NSDUH Annual National Report | CBHSQ Data [Internet]. https://www.samhsa.gov/data/report/2019-nsduh-annual-national-report. Accessd 9 Nov 2021

34.

Bachhuber M, Arnsten JH, Wurm G. Use of cannabis to relieve pain and promote sleep by customers at an adult use dispensary. J Psychoact Drugs. 2019;51:400–4. https://doi.org/10.1080/02791072.2019.1626953.CrossRef

35.

Reynolds IR, Fixen DR, Parnes BL, Lum HD, Shanbhag P, Church S, et al. Characteristics and patterns of marijuana use in community-dwelling older adults. J Am Geriatr Soc. 2018;66:2167–71. https://doi.org/10.1111/jgs.15507.PubMedPubMedCentralCrossRef

36.

Yang KH, Kaufmann CN, Nafsu R, Lifset ET, Nguyen K, Sexton M, et al. Cannabis: an emerging treatment for common symptoms in older adults. J Am Geriatr Soc. 2021;69:91–7. https://doi.org/10.1111/jgs.16833.PubMedCrossRef

37.

Sarvet AL, Wall MM, Keyes KM, Olfson M, Cerdá M, Hasin DS. Self-medication of mood and anxiety disorders with marijuana: higher in states with medical marijuana laws. Drug Alcohol Depend. 2018;186:10–5. https://doi.org/10.1016/j.drugalcdep.2018.01.009.PubMedPubMedCentralCrossRef

38.

Lum HD, Arora K, Croker JA, Qualls SH, Schuchman M, Bobitt J, et al. Patterns of marijuana use and health impact: a survey among older Coloradans. Gerontol Geriatr Med. 2019;5:2333721419843707. https://doi.org/10.1177/2333721419843707.PubMedPubMedCentralCrossRef

39.

Hamilton HA, Brands B, Ialomiteanu AR, Mann RE. Therapeutic use of cannabis: prevalence and characteristics among adults in Ontario, Canada. Can J Public Health. 2017;108:e282–7. https://doi.org/10.17269/cjph.108.6130.PubMedPubMedCentralCrossRef

40.

Mücke M, Phillips T, Radbruch L, Petzke F, Häuser W. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2018;3(3): CD012182. https://doi.org/10.1002/14651858.cd012182.pub2.PubMedCrossRef

41.

Corroon JM, Mischley LK, Sexton M. Cannabis as a substitute for prescription drugs—a cross-sectional study. J Pain Res. 2017;10:989–98. https://doi.org/10.2147/jpr.s134330.PubMedPubMedCentralCrossRef

42.

Ishida JH, Wong PO, Cohen BE, Vali M, Steigerwald S, Keyhani S. Substitution of marijuana for opioids in a national survey of US adults. PLoS ONE. 2019;14: e0222577. https://doi.org/10.1371/journal.pone.0222577.PubMedPubMedCentralCrossRef

43.

Sexton M, Cuttler C, Finnell JS, Mischley LK. A cross-sectional survey of medical cannabis users: patterns of use and perceived efficacy. Cannabis Cannabinoid Res. 2016;1:131–8. https://doi.org/10.1089/can.2016.0007.PubMedPubMedCentralCrossRef

44.

Choi NG, Marti CN, DiNitto DM, Choi BY. Older adults’ marijuana use, injuries, and emergency department visits. Am J Drug Alcohol Abuse. 2018;44:215–23. https://doi.org/10.1080/00952990.2017.1318891.PubMedCrossRef

45.

Han BH, Funk-White M, Ko R, Al-Rousan T, Palamar JJ. Decreasing perceived risk associated with regular cannabis use among older adults in the United States from 2015 to 2019. J Am Geriatr Soc. 2021;69(9):2591–7. https://doi.org/10.1111/jgs.17213.PubMedCrossRef

46.

Perron BE, Holt KR, Yeagley E, Ilgen M. Mental health functioning and severity of cannabis withdrawal among medical cannabis users with chronic pain. Drug Alcohol Depend. 2019;194:401–9. https://doi.org/10.1016/j.drugalcdep.2018.09.029.PubMedCrossRef

47.

Scott EP, Brennan E, Benitez A. a systematic review of the neurocognitive effects of cannabis use in older adults. Curr Addict Rep. 2019;6:443–55. https://doi.org/10.1007/s40429-019-00285-9.PubMedPubMedCentralCrossRef

48.

Lloyd SL, Striley CW. Marijuana use among adults 50 years or older in the 21st century. Gerontol Geriatr Med. 2018;4:2333721418781668. https://doi.org/10.1177/2333721418781668.PubMedPubMedCentralCrossRef

49.

Lowry DE, Corsi DJ. Trends and correlates of cannabis use in Canada: a repeated cross-sectional analysis of national surveys from 2004 to 2017. CMAJ Open. 2020;8:E487–95. https://doi.org/10.9778/cmajo.20190229.PubMedPubMedCentralCrossRef

50.

Ishida JH, Zhang AJ, Steigerwald S, Cohen BE, Vali M, Keyhani S. Sources of information and beliefs about the health effects of marijuana. J Gen Intern Med. 2020;35:153–9. https://doi.org/10.1007/s11606-019-05335-6.PubMedCrossRef

51.

Bertram JR, Porath A, Seitz D, Kalant H, Krishnamoorthy A, Nickerson J, et al. Canadian guidelines on cannabis use disorder among older adults. Can Geriatr J. 2020;23:135–42. https://doi.org/10.5770/cgj.23.424.PubMedPubMedCentralCrossRef

Title: Medical Cannabis Use Among Older Adults in Canada: Self-Reported Data on Types and Amount Used, and Perceived Effects
Authors: Shankar Tumati
Krista L. Lanctôt
RuoDing Wang
Abby Li
Andrew Davis
Nathan Herrmann
Publication date: 01-02-2022
Publisher: Springer International Publishing
Keywords: Opioids
Opioids
Published in: Drugs & Aging / Issue 2/2022
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI: https://doi.org/10.1007/s40266-021-00913-y

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Medical Cannabis Use Among Older Adults in Canada: Self-Reported Data on Types and Amount Used, and Perceived Effects

Abstract

Background

Methods

Results

Interpretation

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Interpretation

Please log in to get access to this content

Other articles of this Issue 2/2022

Which Potentially Inappropriate Medications List Can Detect Patients At Risk of Readmissions in the Older Adult Population Admitted for Falls? An Observational Multicentre Study Using a Clinical Data Warehouse

Topical Pharmacotherapy for Actinic Keratoses in Older Adults

Neuropsychiatric Systemic Lupus Erythematosus in Older Adults: Diagnosis and Management

Pharmacological Treatment in the Management of Glenohumeral Osteoarthritis

Complement Mediators in Development to Treat Age-Related Macular Degeneration

Correction to: Assessment of Comorbidity Burden and Treatment Response: Reanalysis of the SCD-HEFT Trial

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page